NO963120L - Monoklonale antistoffer som binder til tumorrejeksjons-antigenforlöperen MAGE-3, rekombinant MAGE-1, og MAGE-1 avledete immunogene peptider - Google Patents

Monoklonale antistoffer som binder til tumorrejeksjons-antigenforlöperen MAGE-3, rekombinant MAGE-1, og MAGE-1 avledete immunogene peptider

Info

Publication number
NO963120L
NO963120L NO963120A NO963120A NO963120L NO 963120 L NO963120 L NO 963120L NO 963120 A NO963120 A NO 963120A NO 963120 A NO963120 A NO 963120A NO 963120 L NO963120 L NO 963120L
Authority
NO
Norway
Prior art keywords
mage
monoclonal antibodies
bind
tumor rejection
recombinant
Prior art date
Application number
NO963120A
Other languages
English (en)
Other versions
NO963120D0 (no
Inventor
Yao-Tseng Chen
Elisabeth Stockert
Yachi Chen
Pilar Garin-Chesa
Wolfgang J Rettig
Pierre Van Der Bruggen
Thierry Boon-Falleur
Lloyd Old
Original Assignee
Ludwig Inst Cancer Res
Sloan Kettering Inst Cancer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Inst Cancer Res, Sloan Kettering Inst Cancer filed Critical Ludwig Inst Cancer Res
Publication of NO963120D0 publication Critical patent/NO963120D0/no
Publication of NO963120L publication Critical patent/NO963120L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO963120A 1994-02-01 1996-07-26 Monoklonale antistoffer som binder til tumorrejeksjons-antigenforlöperen MAGE-3, rekombinant MAGE-1, og MAGE-1 avledete immunogene peptider NO963120L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/190,411 US5541104A (en) 1991-05-23 1994-02-01 Monoclonal antibodies which bind to tumor rejection antigen precursor mage-1
PCT/US1995/000095 WO1995020974A1 (en) 1994-02-01 1995-01-05 Monoclonal anbibodies which bind to tumor rejection antigen precursor mage-1, recombinant mage-1, and mage-1 derived immunogenic peptides

Publications (2)

Publication Number Publication Date
NO963120D0 NO963120D0 (no) 1996-07-26
NO963120L true NO963120L (no) 1996-09-30

Family

ID=22701236

Family Applications (1)

Application Number Title Priority Date Filing Date
NO963120A NO963120L (no) 1994-02-01 1996-07-26 Monoklonale antistoffer som binder til tumorrejeksjons-antigenforlöperen MAGE-3, rekombinant MAGE-1, og MAGE-1 avledete immunogene peptider

Country Status (16)

Country Link
US (2) US5541104A (no)
EP (1) EP0752876B1 (no)
JP (1) JPH09511389A (no)
CN (1) CN1145032A (no)
AT (1) ATE215831T1 (no)
AU (1) AU686314B2 (no)
CA (1) CA2182369A1 (no)
DE (1) DE69526339T2 (no)
DK (1) DK0752876T3 (no)
ES (1) ES2174931T3 (no)
FI (1) FI963033A7 (no)
NO (1) NO963120L (no)
NZ (1) NZ279377A (no)
PT (1) PT752876E (no)
WO (1) WO1995020974A1 (no)
ZA (1) ZA95786B (no)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5925729A (en) * 1991-05-23 1999-07-20 Ludwig Institute For Cancer Research Tumor rejection antigen precursors, tumor rejection antigens and uses thereof
USRE40089E1 (en) * 1991-05-23 2008-02-19 Ludwig Institute For Cancer Research Nucleic acid molecules encoding the MAGE-1 tumor rejection antigen precursor
US6060257A (en) * 1994-06-03 2000-05-09 Ludwig Institute For Cancer Research Tumor rejection antigens presented by HLA-B44 molecules, and uses thereof
KR0185334B1 (ko) * 1995-11-02 1999-04-01 김은영 인간 혈장 아포지단백질 비-100에 결합하는 생쥐 항체를 암호하는 씨디엔에이
US5908778A (en) * 1996-10-03 1999-06-01 Ludwig Institute For Cancer Research Mage-10 encoding cDNA, the tumor rejection antigen precursor mage-10, antibodies specific to the molecule, and uses thereof
EP1039926A1 (en) * 1997-12-18 2000-10-04 G.D. SEARLE & CO. Venezuelan equine encephalitis virus vectors expressing tumor-associated antigens to induce cancer immunity
PT1053325E (pt) 1998-02-05 2006-05-31 Glaxosmithkline Biolog Sa Derivados de antigenios associados a tumores da familia mage e, sequencias de acidos nucleicos que os codificam, utilizados para a preparacao de proteinas de fusao e de composicoes para vacinacao.
US7157091B1 (en) 1999-06-18 2007-01-02 Ludwig Institute For Cancer Research MAGE-A1 peptides presented by HLA class II molecules
DK1282702T3 (da) 2000-05-10 2007-04-02 Sanofi Pasteur Ltd Immunogene polypeptider, som er kodet af KAGE-minigener, og anvendelser deraf
WO2002083945A2 (en) 2001-04-12 2002-10-24 Imperial College Innovations Limited Diagnosis and treatment of cancer: i
AU2004280608B2 (en) * 2002-04-09 2012-04-05 Sanofi Pasteur, Inc. Modified CEA/B7 vector
EP1864691B1 (en) 2002-04-09 2011-07-20 Sanofi Pasteur Limited Modified CEA nucleic acid and expression vectors
FR2889959A1 (fr) * 2005-09-01 2007-03-02 Commissariat Energie Atomique Epitopes t cd4+ des antigenes mage-a restreints a hla-dp4 et leurs applications
WO2008039874A2 (en) 2006-09-26 2008-04-03 Cedars-Sinai Medical Center Cancer stem cell antigen vaccines and methods
WO2008039974A2 (en) 2006-09-28 2008-04-03 Cedars-Sinai Medical Center Cancer vaccines and vaccination methods
PL2328923T3 (pl) 2008-09-02 2016-06-30 Cedars Sinai Medical Center Epitopy CD133
AU2010298025B2 (en) 2009-09-25 2016-04-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to HIV-1 and their use
GB201120860D0 (en) 2011-12-05 2012-01-18 Cambridge Entpr Ltd Cancer immunotherapy
US10137182B2 (en) 2013-02-14 2018-11-27 Immunocellular Therapeutics, Ltd. Cancer vaccines and vaccination methods
WO2016094309A1 (en) 2014-12-10 2016-06-16 Myosotis Inhibition of tnf signaling in cancer immunotherapy
IL274572B2 (en) 2015-07-16 2024-01-01 Biolinerx Ltd Compositions and methods for treating cancer
GB201519340D0 (en) 2015-11-02 2015-12-16 Cambridge Entpr Ltd Methods of T-lymphocyte expansion
GB201519481D0 (en) 2015-11-04 2015-12-16 Cancer Rec Tech Ltd Immunomodulatory antibodies
GB201616238D0 (en) 2016-09-23 2016-11-09 Adaptimmune Ltd Modified T cells
PT3565828T (pt) 2017-01-05 2022-02-08 Kahr Medical Ltd Proteína de fusão sirp1 alfa-41bbl e seus métodos de utilização
LT3565579T (lt) 2017-01-05 2023-09-11 Kahr Medical Ltd. Pd1-41bbl sulietas baltymas ir jo panaudojimo būdai
GB201700345D0 (en) 2017-01-09 2017-02-22 F-Star Beta Ltd Conditional agonists of immune responses
IL250916A0 (en) 2017-03-02 2017-06-29 Geiger Benjamin Methods for growing t cells in culture and their use
WO2019006003A1 (en) 2017-06-27 2019-01-03 The Trustees Of Princeton University COMPOSITIONS AND METHODS FOR IMPROVING IMMUNOTHERAPY
GB201713078D0 (en) 2017-08-15 2017-09-27 Adaptimmune Ltd T Cell Modification
JP2021515588A (ja) 2018-01-26 2021-06-24 ケンブリッジ エンタープライズ リミティッド ペプチド交換蛋白質
US12134638B2 (en) 2018-07-11 2024-11-05 Kahr Medical Ltd. SIRPalpha-4-1BBL variant fusion protein and methods of use thereof
GB201811410D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd OX40 Binding molecules
GB201811404D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-CD137 Antibodies
GB201811408D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd CD137 Binding Molecules
WO2020041662A1 (en) 2018-08-24 2020-02-27 The Trustees Of Princeton University Immunotherapy with metabolic enzyme expression
GB201820444D0 (en) 2018-12-14 2019-01-30 Adaptimmune Ltd Marker for T cell expansion
US20220267409A1 (en) 2019-07-11 2022-08-25 Kahr Medical Ltd. Heterodimers and methods of use thereof
GB201911954D0 (en) 2019-08-20 2019-10-02 Adaptimmune Ltd Lentiviral transduction methods
WO2021137231A1 (en) 2019-12-31 2021-07-08 Kahr Medical Ltd. Methods of culturing t cells with a 4-1bbl fusion polypeptide and uses of same
US20230048361A1 (en) 2019-12-31 2023-02-16 Kahr Medical Ltd. Methods of culturing t cells and uses of same
IL276599A (en) 2020-08-09 2022-03-01 Yeda Res & Dev T cell receptor unique to mage-a1 and its uses
CN117157318A (zh) 2020-12-30 2023-12-01 免疫治疗有限公司 抗hvem抗体
EP4430402A1 (en) 2021-11-09 2024-09-18 T-Knife GmbH Methods of selecting a patient for treatment of a mage-a1 positive solid tumor, of predicting whether a patient being diagnosed with mage-a1 positive solid tumor will be responsive to treatment of this tumor and of treating a patient being diagnosed with such a mage-a1 positive solid tumor as well as corresponding pharmaceutical compositions and diagnostic kits
GB202303250D0 (en) 2023-03-06 2023-04-19 King S College London Method and compounds
WO2025155971A1 (en) 2024-01-19 2025-07-24 Immunomic Therapeutics, Inc Anti-activin receptor 1c (alk-7) receptor antibodies

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5342774A (en) * 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
KR950003005B1 (ko) * 1992-04-09 1995-03-29 주식회사 진흥전자 자동소변세척기
DE4224542A1 (de) * 1992-07-24 1994-01-27 Deutsches Krebsforsch Verfahren zur Herstellung von monoklonalen MHC Klasse I-puls-Peptid-restringierten Antikörpern

Also Published As

Publication number Publication date
DK0752876T3 (da) 2002-05-21
CN1145032A (zh) 1997-03-12
EP0752876A4 (en) 1999-07-07
EP0752876A1 (en) 1997-01-15
CA2182369A1 (en) 1995-08-10
US5843448A (en) 1998-12-01
ATE215831T1 (de) 2002-04-15
AU1597995A (en) 1995-08-21
US5541104A (en) 1996-07-30
DE69526339T2 (de) 2003-01-02
EP0752876B1 (en) 2002-04-10
FI963033A0 (fi) 1996-07-31
AU686314B2 (en) 1998-02-05
WO1995020974A1 (en) 1995-08-10
FI963033L (fi) 1996-07-31
NO963120D0 (no) 1996-07-26
JPH09511389A (ja) 1997-11-18
FI963033A7 (fi) 1996-07-31
ES2174931T3 (es) 2002-11-16
ZA95786B (en) 1995-10-09
PT752876E (pt) 2002-09-30
DE69526339D1 (de) 2002-05-16
NZ279377A (en) 1997-07-27

Similar Documents

Publication Publication Date Title
NO963120D0 (no) Monoklonale antistoffer som binder til tumorrejeksjons-antigenforlöperen MAGE-3, rekombinant MAGE-1, og MAGE-1 avledete immunogene peptider
DE69433663D1 (de) Antikörper gegen menschliches prostatspezifisches drüsenkallikrein
RU94045919A (ru) Антитела, клетки, полипептид, днк векторы, способ получения полипептида, способ получения антитела, фармацевтическая композиция
EP0939653A4 (en) Humanization of anti-carcinoembryonic antigen anti-idiotypic antibodies and its use as a tumor vaccine and for labeling
ATE208820T1 (de) Humanisierte antikoerper
GB2383331A (en) Monoclonal antibody DS6 Tumor-associated antigen CA6 and methods of use thereof
ATE377027T1 (de) Tetravalente antikörperkonstrukte
DE60139542D1 (de) Methoden zur herstellung humaner monoklonaler antikörper
EA199800973A1 (ru) Полипептид белка-106 наружной мембраны moraxella catarrhalis, последовательность гена и их применение
ATE505542T1 (de) Tumorassoziierte antigenderivate der mage-familie,zur herstellung von fusionsproteinen mit t-helper epitope und zusammensetzungen zur impfung
ES8601704A1 (es) Un polipeptido sintetico
WO1998022510A3 (en) Methods for the production of chicken monoclonal antibodies
DE69634092D1 (de) Herstellung von antikörpern
ATE349468T1 (de) Mehrantigenisches peptid enthaltend mehrere kopien eines epitopes von einem ablagerungsformenden polypeptid und dessen verwendung
BG101038A (bg) Супресия на растежа на туморни клетки посредствомсиндекан- 1 ектоучастък
RU2004108115A (ru) Рекомбинантные антитела и композиции, а также способы их создания и использования
KR900701318A (ko) 항-사람 고분자량- 흑색종 관련 항원에 대한 항-이디오 타입 항체
AU2911289A (en) Carcinoma-associated antigens, and antibodies which recognize these antigens
ATE348842T1 (de) Anti-pilyrosporum ovale igy und dessen verwendung
DK0831881T3 (da) CETP til forøgelse af HDL-cholesterolniveau
CA2165672A1 (en) Antibodies specific for human prostate glandular kallikrein
HUP0001270A2 (en) Compositions and methods for the treatment and diagnosis of breast cancer
Chen et al. Monoclonal antibodies which bind to tumor rejection antigen precursor MAGE-1
ZHANG Preparation of monoclonal antibodies against SARS coronavirus nucleocapsid protein and preliminary analysis of antigenic epitopes
TW200500465A (en) Novel humanized anti-vap-1 monoclonal antibody